Tirzepatide's therapeutic dose: when treatment really begins

You've just been approved for Mounjaro and you're holding the 2.5 mg pen, now what?

Picture the scene: your consultation is approved, the pen arrives, and you're ready for results. The instructions say 2.5 mg for the first four weeks, and you search online to find out when you'll actually start losing weight. The honest answer is that this first pen is your system's warm-up act. Its job is to reduce the chance of nausea and other gastrointestinal side effects during the early weeks, not to deliver the full appetite-suppressing effect of the medicine.

Tirzepatide works by activating both GIP and GLP-1 receptors, two gut-hormone pathways involved in hunger signalling and blood-sugar regulation. At 2.5 mg, that activation is mild by design. As you step up through the dose schedule, the effect strengthens. This is why the term "therapeutic dose" in everyday clinical use refers to the doses at and above 5 mg, where the medicine is working at a level likely to produce meaningful changes in appetite and, over time, body weight. A practical check you can do in under a minute: look at your dispensed pen's label and confirm whether it matches the dose your prescriber documented, any mismatch is worth raising with your clinical team before you inject.

The NHS medicines page for tirzepatide confirms the six UK-licensed strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Treatment starts at the lowest and typically advances in four-week steps. The pace is guided by your prescriber based on how your body responds and tolerates each level.

Where the weight-loss evidence sits across the dose range

The largest body of evidence comes from the SURMOUNT programme, with SURMOUNT-1 being the pivotal trial for weight management. Over 72 weeks, adults without diabetes who reached the 15 mg dose lost around 20–21% of body weight on average. Those at 10 mg averaged roughly 19%, and 5 mg participants around 15%, all meaningfully above placebo.

What this tells you is that the therapeutic effect scales with dose, within each person's tolerance ceiling. Not everyone reaches 15 mg; some people achieve excellent results at 10 mg and their prescriber keeps them there. Others tolerate the top dose well and see the greatest benefit. The NICE appraisal of tirzepatide (TA1026) references these figures and forms part of the basis for the medicine's UK recommendation for adults with a BMI of 35 or above plus at least one weight-related condition, with lower BMI thresholds applying for some ethnic backgrounds under UK guidance.

For a fuller breakdown of all six strengths and what the clinical data shows at each level, the tirzepatide doses guide covers this in detail. If you're specifically weighing up what the 5 mg pen looks like in practice, there's a dedicated page on Mounjaro 5 mg worth reading alongside this one.

Why your prescriber (not the dose schedule) is the real guide

The titration ladder is a framework, not a conveyor belt. A prescriber reviewing your case may slow a dose increase if side effects are notable, hold your dose at a level that's working well, or pause escalation temporarily for medical reasons. They may also consider whether you've met the threshold the NICE guidance points to: if less than 5% of body weight has been lost after six months at the highest tolerated dose, continuing treatment is subject to review.

This is worth knowing because it means the "right" therapeutic dose is personal, not universal. Someone doing well at 7.5 mg is not underachieving because they haven't reached 15 mg. The goal is meaningful, sustainable weight reduction with a side-effect profile you can live with, and that balance is different for each person. You can read more about how the full dose range is structured on the tirzepatide dose overview page, or explore the broader question of what doses Mounjaro comes in if you're earlier in your research.

Cost is often part of the picture when people are thinking about dose increases. Private treatment prices vary by dose and provider; for context on how pricing works in the UK market, the Mounjaro cost guide lays out what drives the numbers without any hidden extras.

Microdosing and 'sub-therapeutic' use, a note on the evidence gap

Some people ask whether staying at 2.5 mg indefinitely, or using tirzepatide at lower-than-licensed doses to minimise side effects, has a clinical rationale. This is sometimes discussed informally as "microdosing". The short answer is that the clinical trial evidence base is built on the licensed dose schedule, and there is no robust published data for sustained sub-therapeutic use in weight management. A prescriber will weigh your individual circumstances if this comes up, it's not a decision to make independently.

If you've come across this topic specifically, the page on tirzepatide microdosing addresses what the term means and what is actually known. For a broader overview of the medicine itself, the Mounjaro information page is a good starting point, and the therapeutic dose deep-dive goes further into the clinical picture. Speak to our prescribers if you have questions about your specific dose situation, a free consultation is the right place to start rather than adjusting anything yourself.